Treatment with tenofovir disoproxil fumarate (TDF) does not increase the risk of fractures, according to French research published in the online edition of the Journal of Acquired Immune Deficiency Syndromes. Findings of the case-controlled study showed there was no association between tenofovir disoproxil and fractures in any of the statistical models designed by the authors.…
Read More » […]